Caspases are aspartate-speci®c cysteine proteases that play a pivotal role in drug-induced cell death. We designed RT ± PCR assays to analyse the expression of CASP-3, CASP-4, CASP-6 and the long and short isoforms of CASP-2 genes in human cells. These genes heterogeneously coexpress in leukemic cell lines and bone marrow samples from patients with de novo acute myelogenous leukemia at diagnosis. Treatment of U937 and HL60 leukemic cells and HT29 colon carcinoma cells with the topoisomerase II inhibitor etoposide upregulates CASP-2 and CASP-3 genes in these cells before inducing their apoptosis. This eect of etoposide is not observed in K562 cells and bcl-2-transfected U937 cells which are less sensitive to drug-induced apoptosis. Nuclear run-on experiments demonstrate that etoposide increases CASP gene transcription in U937 cells, an eect that is prevented by Bcl-2 overexpression. Upregulation of CASP genes is associated with an enhanced synthesis of related procaspases that precedes the appearance of apoptosis markers including caspase-3 activation, poly(ADP-ribose) polymerase cleavage and internucleosomal DNA fragmentation. These results suggest that the ability of tumor cells to upregulate CASP-2 and CASP-3 genes in response to cytotoxic drugs could be predictive of their sensitivity to druginduced apoptosis.
Introduction
Genetic analyses performed in Caenorrhabditis elegans identi®ed the genes that are necessary for apoptosis during embryonic development of this nematode: ced-9 and a long isoform of ced-4 encode negative regulators that suppress inappropriate cellular suicide while ced-3 and a short isoform of ced-4 encode eector components of the cell death pathway (Hentgartner and Horvitz, 1994a; Shaham and Horvitz, 1996) . The mammalian homolog of ced-9 is bcl-2 which can substitute functionally for ced-9 (Hentgartner and Horvitz, 1994b). The CED-3 protein demonstrates signi®cant homologies with the interleukin-1b converting enzyme (ICE) family of cysteine proteases, now referred as caspases Alnemri et al., 1996) . These aspartate-speci®c proteases exist in the cytosol as proenzymes that are proteolytically activated at internal aspartate residues to form a heterodimeric catalytic domain (Takahashi and Earnshaw, 1996) . Cell death induced by mammalian CED-3-like caspases can be inhibited by overexpression of Bcl-2 Meisenholder et al., 1996; Armstrong et al., 1996; Monney et al., 1996) and the Bcl-2-related protein Bcl-X L (Erhardt and Cooper, 1996) . While no homolog of ced-4 has been so far identi®ed in mammals, a CED-4-like protein could mediate protection by Bcl-2 against cell death induced by CED-3-related proteases (Chinnaiyan et al., 1997; Wu et al., 1997) .
At least ten caspases have been identi®ed in humans, most of them inducing apoptosis when overexpressed (Miura et al., 1993; Kumar et al., 1994) . At least in vitro, some of them are capable of activating others in a manner analogous to the protease zymogens of the coagulation or complement cascades (FernandesAlnemri et al., 1996; Greidinger et al., 1996; . Despite the rapidly growing knowledge of the structure, expression and substrate-recognition properties of these proteases, it remains uncertain whether each caspase has a speci®c substrate for mediating apoptosis in vivo or if some of them are redundant, cleaving the same substrate. It is noteworthy that mice knocked-out for CASP-1 (ICE) gene develop normally although their thymocytes demonstrate a speci®c resistance to Fas-mediated apoptosis (Kuida et al., 1995) while CASP-3-de®cient mice do not show any alteration of their thymocyte susceptibility to various apoptotic stimuli but show profound alterations of their brain development and die at 1 ± 3 weeks of age (Kuida et al., 1996) . These results suggest that caspase-1 is speci®cally involved in Fas-mediated cell death while caspase-3 plays a major role in the normal development of some cells of the brain.
The epipodophyllotoxin etoposide (VP-16) is a topoisomerase II-reactive agent commonly used for the treatment of various human tumors. This cytotoxic drug produces DNA double-strand breaks by stabilizing a transient intermediate of the topoisomerase reaction (Pommier, 1997) . These DNA damage are thought to be a critical event for etoposide cytotoxic activity. As many other cytotoxic drugs, etoposide kills tumor cells by inducing their apoptosis . The ability of malignant cells to undergo apoptotic cell death following DNA damage is the ultimate determinant of their sensitivity to these drugs Dubrez et al., 1995) . We have previously identi®ed several steps in the proteolytic pathway that leads to apoptotic DNA fragmentation in human leukemic cells treated with etoposide (Dubrez et al., 1996) . We observed that a protease sensitive to the CED-3-like caspase tetrapeptide inhibitor DEVD played a central role in this pathway. The relation-ships between the expression of CASP genes in tumor cells and their sensitivity to etoposide-induced apoptosis remained unknown. This question was addressed in the present study.
Results

Heterogeneous expression of CASP genes in human leukemic cell lines
Three groups of caspases have been identi®ed, based on structural homologies . We designed reverse transcriptase polymerase chain reaction (RT ± PCR) assays to study the expression of CASP genes in tumor cells. The studied CASP genes were selected in the three caspase groups and included: (1) the long and the short isoforms of CASP-2 gene encoding procaspase-2L (ICH-1L) and procaspase-2S (ICH-1S) respectively (Wang et al., 1994) ; (2) two CASP genes encoding CED3-related procaspases, namely CASP-3 encoding procaspase-3 (CPP32/ Yama/Apopain) (Fernandes Alnemri et al., 1994; Tewari et al., 1995; Nicholson et al., 1995) and CASP-6 encoding procaspase-6a (Mch-2a) (Fernandes-Alnemri et al., 1995a) ; and (3) CASP-4 encoding the ICE-related procaspase-4 (ICH-2/TX/ ICE rel -II) (Kamens et al., 1995; Faucheu et al., 1995; Munday et al., 1995) (Table 1) . Their expression was ®rst analysed in ®ve human leukemic cell lines (BV173, HL60, U937, K562 and KCL22 cell lines) in exponential phase of growth without addition of any apoptosis-inducing agent (Figure 1a and b) . The expression of each CASP gene was related to the b2 microglobulin gene expression measured in parallel in every cell line. Ethidium bromide staining of the agarose gel after migration of the PCR products identi®ed a band of the expected size for each pair of primers ( Figure 1a ). The speci®city of this amplification product was systematically con®rmed both by hybridizing the generated band with a speci®c 30-mer oligonucleotide and by directly sequencing the band of the expected size (not shown). CASP-4 gene expression was not detected in K562 cells. The expression of the other studied CASP genes was heterogeneous among (Figure 1a and b) . For example, the short isoform of CASP-2 was sixfold more expressed in K562 cells compared to HL60 cells and the expression of CASP-6 was 28-fold lower in HL60 cells compared to KCL22 cells (Figure 1b) . These results were highly reproducible from multiple mRNA preparations. The sensitivity of the studied cell lines to apoptotic DNA fragmentation induced by continuous exposure to 100 mM etoposide was measured by the use of a ®lter elution assay (Figure 1c) . These experiments con®rmed that K562 and KCL22 cell lines were less sensitive to etoposide-induced cell death than the three other studied cell lines (Dubrez et al., 1995) . No clear relationship was identi®ed between the pro®le of expression of the studied CASP genes and the cell line sensitivity to etoposide-induced apoptosis.
Heterogeneous expression of CASP genes in clinical bone marrow samples from de novo acute myelogenous leukemias
We checked whether the heterogeneous expression of CASP genes identi®ed in leukemic cell lines was also observed in bone marrow samples from patients with de novo acute myeloblastic leukemia (AML). We selected three CASP gene isoforms whose expression was determined by RT ± PCR ampli®cation in ®fteen AML bone marrow samples, two bone marrow samples obtained from healthy donors and the human leukemic cell line U937 (Figure 2a and b). Results were analysed on ethidium bromide-stained agarose gel after migration of PCR ampli®cation products ( Figure 2a ) and con®rmed by hybridization with speci®c 30-mer oligonucleotides (not shown). The b2 microglobulin gene expression was studied in parallel and the ratio of the expression of each CASP gene to the expression of the b2 microglobulin gene was determined for every sample studied ( Figure 2b ). These experiments indicated that the expression of CASP genes was also heterogeneous in clinical samples from patients with AML. CASP-3 gene was more expressed in U937 cells and in most AML bone marrow samples studied than in the two normal bone marrow samples. Conversely, the expression of the short isoform of CASP-2 gene was lower in U937 cells and in a majority of clinical AML samples compared to normal bone marrow.
Etoposide eects on the expression of CASP genes and the appearance of apoptotic markers in U937 cells
To determine whether the expression of caspases was regulated at the mRNA level during etoposide-induced apoptosis, we studied the kinetics of CASP-3, CASP-2L and CASP-2S gene expression in U937 cells treated with 50 mM etoposide. The expression of CASP genes either remained stable (CASP-2L) or increased (CASP-2S and CASP-3) during the ®rst hours of drug exposure ( Figure  3a ), before the appearance of apoptotic markers. Procaspase-2L protein level decreased while procaspase-2S accumulated in parallel with the related CASP gene isoform mRNA. Apoptosis markers included the activation of procaspase-3 whose level decreased when caspase-3-p19 and caspase-3-p17 active fragments appeared simultaneously with the cleavage of the p116 PARP protein into a 85 kDa fragment ( Figure 3b ) and the appearance of a DNA ladder ( Figure 3c ). Starting with the occurrence of these markers, CASP gene expression decreased progressively until complete disappearance in ethidium bromide-stained agarose gel, 24 h after the beginning of drug exposure, when the majority of cells are apoptotic (Dubrez et al., 1995) .
Dierential modulation of CASP gene expression in HL60 and K562 cells
In HL60 cells, which are as sensitive to etoposideinduced apoptosis as U937 cells, continuous exposure to 50 mM etoposide also increased the expression of both CASP-2S and CASP-3 genes. In this cell line, CASP-2L mRNA level also increased during the ®rst hours of drug exposure (Figure 4 ). In the K562 cell line, that was much less sensitive to etoposide-induced apoptosis as compared to U937 and HL60 cells, the expression of the three studied CASP gene isoforms remained stable during the ®rst 48 h exposure to 100 mM etoposide (Figure 4 Figure 5a , right panels). In detached cells (Figure 5d ), the expression of both CASP genes and procaspases decreased while the caspase-3-p19 and caspase-3-p17 active fragments appeared.
Eects of bcl-2 gene overexpression upon CASP gene expression in etoposide-treated U937 cells
To further analyse the relationship between cell sensitivity to drug-induced cell death and CASP gene Ethidium bromide-stained PCR ampli®cation products after agarose gel electrophoresis are shown. b2 microglobulin gene expression was used as an internal standard to measure the CASP to b2 microglobulin gene expression ratio from these gels. Results shown are onw of three experiments performed with dierent RNA preparations upregulation, we tested the eect of BCL-2 protein overexpression on etoposide-mediated CASP genes modulation. BCL-2 protein has been demonstrated to inhibit apoptosis downstream of speci®c DNA damage induced by topoisomerase inhibitors (Kamesaki et al., 1993) and upstream of the activation of CED-3-like procaspases Meisenholder et al., 1996) . To address the question whether overexpression of BCL-2 could modify CASP gene modulation in etoposide-treated cells, we transfected bcl-2 gene in the U937 cell line. One of the clones (U4) in which BCL-2 protein was clearly overexpressed (RenvoizeÂ et al., 1997) was selected for further experiments. Overexpression of BCL-2 protein significantly delayed procaspase-3 activation into caspase-3-p19 and caspase-3-p17 fragments, PARP cleavage into its p85 fragment and apoptotic DNA fragmentation occurrence (Figure 6b and c) . In etoposide-treated U4 cells, BCL-2 overexpression prevented both CASP-2S and CASP-3 mRNA level increase that occurs during the ®rst hours of treatment in the parental U937 cells (Figure 6a ).
Mechanisms of CASP gene modulation in etoposidetreated U937 cells
Nuclear run-on transcription experiments, performed in etoposide-treated U937 cells, demonstrated that the transcription of the short isoform of the CASP-2 gene was about sixfold increased when studied 4.5 h after cell exposure to 50 mM etoposide. Transcription of two other studied CASP genes, namely CASP-3 and CASP-6, also increased, although more slightly, in response to etoposide exposure (Figure 7a ). This treatment did not modify a-actin and Bcl-X L gene transcription (Figure 7a ). The same experiments were performed in the U4 clone that overexpresses BCL-2 protein. These experiments demonstrated that BCL-2 overexpression prevented CASP-2s and CASP-3 upregulation in these cells (Figure 7b ). The permanent peptides Z-VAD-CH2F and Z-DEVD-CH2F, which are homologous to sequences speci®cally targeted by ICE-like caspases and CED-3-like caspases, respectively, both prevented etoposideinduced apoptotic DNA fragmentation and PARP cleavage in etoposide-treated U937 cells (Dubrez et al., 1996) . Both Z-VAD and Z-DEVD peptides also eciently suppressed CASP gene expression decrease associated with the cell death process in etoposidetreated U937 cells (Figure 8) .
Discussion
The basal level of several CASP mRNAs was analysed for the ®rst time in a series of human leukemic cell lines and bone marrow samples from patients with de novo AML. It was previously shown that human CASP genes co-expressed in a variety of tissues (Wang et al., 1994) . These genes are more expressed in embryonic compared to adult tissues and are poorly expressed in adult brain compared to any other adult tissue (Fernandes-Alnemri et al., 1994 Kamens et al., 1995; Munday et al., 1995; Duan and Dixit, 1997) . In the human HL60 leukemic cell line, RT ± PCR identi®ed transcripts for at least nine dierent caspases (Martins et al., 1997) . Here, we con®rm coexpression of CASP genes from various CASP-3 gene, that encodes a pro-apoptotic protease (Fernandes-Alnemri et al., 1994; Tewari et al., 1995; Nicholson et al., 1995) , was generally more expressed in fresh leukemic cells and U937 cells compared to normal bone marrow samples. Conversely, the short isoform of CASP-2, that encodes an anti-apoptotic protein (Wang et al., 1994) , was less expressed in leukemic cells than in normal cells. Among the four genes whose expression was analysed in leukemic cell lines, only one, CASP-4, was not detected in one cell line, K562. The low sensitivity of K562 cells to a variety of apoptotic stimuli has been previously related to bcr ± abl overexpression (McGahon et al., 1994) . By analogy with thymocytes from CASP-1-null mice which show defective Fas-mediated apoptosis (Kuida et al., 1995) , the lack of CASP-4 gene expression could contribute to the low sensitivity of K562 cells to apoptotic stimuli. Actually, no clear relationship was identi®ed between the ability of leukemic cell lines to undergo apoptosis when treated with etoposide and the basal expression of the studied CASP genes in these cells. Several reasons could account for this lack of correlation. First, leukemic cell sensitivity to druginduced cell death could be regulated upstream of procaspase activating cleavage, for example by the BCL-2 family of proteins (Chinnayian et al., 1996; Meisenholder et al., 1996; Armstrong et al., 1996; Monney et al., 1996) and other oncogenes (McGahon et al., 1994; Chapman et al., 1994) . Second, functional redundancy in the substrate recognition of caspases could protect the cells from the consequences of the deletion of one or several CASP genes (Kumar et al., 1994) . For example, PARP can be cleaved in vitro by a variety of caspases including caspase-1, -2, -3, -4, -6, -7 and -8 although cleavage by caspase-1, -2 and -4 appears to require high enzyme concentrations (Kaufmann et al., 1993; Nicholson et al., 1995; Fernandes-Alnemri et al., 1995b; Gu et al., 1995a) . Third, heterodimerization between pro-apoptotic and anti-apoptotic isoforms of caspases (Gu et al., 1995b) ; alternative processing of the proenzymes (Alnemri et al., 1995) and/or posttranslational modi®cations of the processed subunits Martins et al., 1997) rather than CASP gene mRNA level could determine whether a cell live or die by apoptosis in response to a given stimulus. For example, two-dimensional analysis identi®ed multiple forms of procaspase-3 during etoposide-induced apoptosis in the human leukemic cell line HL60 (Martins et al., 1997) .
Upregulation of the Nedd2 gene, the mouse CASP-2S gene, has been recently described in an in vivo model of neuronal cell death (Kinoshita et al., 1997) . The present study suggests a relationship between enhanced expression of several CASP genes and cell sensitivity to etoposide-induced apoptosis. In U937 cells, upregulation of CASP-2S and CASP-3 mRNA is related to an increased transcription of these genes that precedes the appearance of apoptotic markers. This upregulation is prevented by BCL-2 protein overexpression. BCL-2 (Chinnayian et al., 1996) was shown to delay etoposide-induced apoptotic cell death by preventing the activation of CED-3-like caspases. Our results suggest that this protein could also prevent the activation of one or several transcriptional factors that regulate the expression of CASP and other apoptosis-related genes. A role for transcriptional factors in apoptosis regulation has been suggested both in the nematode Caenorrhabditis elegans (Metzstein et al., 1996) and in mammals (Inaba et al., 1996) . The process of cell death induced by the p53 tumor suppressor was shown to activate eight cDNAs in the mouse M1 myloid leukemia cell line (Amson et al., 1996) . We reported recently that increased transcription of the gadd153 gene, observed in etoposide-treated U937 cells undergoing apoptosis, was prevented by overexpression of BCL-2 (Eymin et al., 1997) . A good correlation was found between the extent of cellular injury and treatment-induced increase in gadd153 mRNA level (Gately et al., 1996) . Our results suggest that the ability of tumor cells to upregulate the expression of CASP genes in response to a cytotoxic drug could be predictive of their sensitivity to this drug.
The cell death process itself is associated with a downregulation of CASP gene expression. In etoposide-treated U937 cells, the permeant peptides Z-VAD-CH2F and Z-DEVD-CH2F prevent apoptotic DNA fragmentation and PARP cleavage (Dubrez et al., 1996; Slee et al., 1996) . These peptides suppress CASPmRNA degradation associated with the cell death process without inhibiting CASP-3 gene upregulation in etoposide-treated U937 cells. This observation suggests that factors that increase the transcription of some CASP genes in etoposide-treated cells are not activated by caspases.
Multiple procaspases are present in human tumor cells prior to the application of an apoptotic stumulus. This stimulus could either activate proteases from preexisting proenzymes or trigger de novo synthesis of additional procaspases. Whether increased transcription of some CASP genes and the accumulation of the related procaspases are necessary for the apoptotic process to occur remains to be demonstrated. Treatment of HL60 cells with concentrations of cycloheximide and puromycin that inhibit most protein synthesis induces apoptotic cell death, suggesting that de novo protein synthesis is not always necessary for apoptosis to occur (Martins et al., 1977) . In U937 cells treated with etoposide, we observed an accumulation of procaspase-2S that preceded the appearance of apoptosis markers. By the use of the HT29 cell line that grows attached to the plastic¯ask and detach when undergoing apoptosis, we were able to separate pre-apoptotic from apoptotic cells. Etoposide-treated HT29 cells accumulated both CASP genes and caspase proenzymes before detaching from the¯ask. Interestingly, procaspase-2S, that encodes an antiapoptotic protein, was upregulated in both U937 and HT29 cells. One hypothesis is that, in response to apoptotic stimuli, cells accumulate caspases that are neutralized by heterodimerization of proapoptotic with antiapoptotic subunits until the start of the apoptotic process.
Altogether, the present study points out the heterogeneous expression of CASP genes in human tumor cells and suggests that cells that are sensitive to etoposide-induced cell death upregulate CASP-2 and CASP-3 gene expression and synthesize the corresponding procaspases before showing signi®cant apoptotic proteolysis and DNA fragmentation.
Materials and methods
Drug and chemicals
[2-
14 C]thymidine (50 mCi/mmol) was obtained from Amersham (Les Ulis, France). The tetrapeptide inhibitors Z-ValAla-Asp-CH2F (Z-VAD) and Z-Asp-Glu-Val-Asp-CH2F (Z-DEVD) were synthetized by Enzyme System Products (Dublin, CA). Oligonucleotides were synthetized by Eurogentec (Angers, France). Etoposide and other chemicals were obtained from Sigma-Aldrich laboratories (St Quentin Fallavier, France).
Cells, cell culture and transfection
The human leukemic cell lines BV173, HL60, U937, K562 and KCL22 were grown in suspension in RPMI 1640 medium (BioWhittaker, Fontenay-sous-bois, France) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum and 2 mM L-glutamine in an atmosphere of 95% air and 5% CO 2 . Cell viability was determined using the trypan blue exclusion assay. Etoposide stock solution (20 mM), prepared by diluting the drug in dimethyl sulphoxide (DMSO), was conserved at 7208C for less than 1 month. The ®nal concentration of DMSO in the culture medium never exceed 1% (vol/vol), which was non toxic to the cells. Cells were resuspended at a density of 1.5610 6 /ml in fresh medium before treatment. Bone marrow leukemic cells were obtained with informed consent from patients with de novo acute myelogenous leukemia at diagnosis, before initiation of any treatment. Samples were sent by overnight mail for immediate RNA extraction and cDNA preparation. Normal bone marrow was obtained from healthy donors with informed consent. Blast cells and normal bone marrow mononuclear cells were isolated on ®coll-hypaque (Eurobio, France).
Reverse transcriptase-polymerase chain reaction RT ± PCR was performed as previously described (Koos and Seidel, 1989) . Total RNA was isolated with RNA Plus TM (Bioprobe Systems, Montreuil-sous-bois, France) from either dierent leukemic cell lines treated or not with etoposide or bone marrow samples from patients with AML. RNA was reverse transcribed by M-MLV reverse transcriptase (Gibco, Cergy Pontoise, France) with random primers (pdN6, Boerhinger-Manheim, Germany). Sense and anti-sense primers used to amplify human CASP and b2 microglobulin genes as well as the size of ampli®ed products are indicated in Table 1 . For each studied gene, primers were located in separate exons in genomic DNA so that we could eliminate the possibility of genomic DNA contamination. The following conditions were used for the PCR reactions: 16reaction buer (Eurobio, Les Ulis, France), 1.5 ± 2.5 mM MgCl 2 optimized according to each pair of primers, 200 mM dNTP, 1 mM of each primer and 2.5 U of Taq DNA polymerase (Eurobio, Les Ulis, France) in a total volume of 50 ml. DNA was denatured for 1 min at 948C prior to 29 ± 38 PCR cycles, depending of the primer used. Ampli®cation was carried out on a PTC 150 (Prolabo, Fontenay-sous-bois, France). The PCR products were analysed on 1.2% agarose gels. The ampli®ed DNA was stained with ethidium bromide and the¯uorescence intensity was detected by video camera and measured using Phoretix 1D software (Phoretix-International, Newcastle, England). All the results were normalized with the expression of the b2 microglobulin gene.
Nuclear run-on assay
The relative transcription rates of CASP-2, CASP-3 and CASP-6 genes was studied in etoposide-treated U937 cells by the use of a previously described method (Srivastava et al., 1993) . Brie¯y, untreated and etoposide-treated (50 mM for 3 h) U937 cells were lysed in a lysis buer (Tris-HCl, 10 mM, pH 7.4, NaCl 10 mM, MgCl 2 3 mM NP-40 0.5%) and nuclei were harvested by centrifugation. For run-on reactions, 200 ml of a 26 reaction mixture (Tris-HCl, 10 mM, pH 8.0, KCl 300 mM, MgCl 2 5 mM, ATP 1 mM, CTP 1 mM, GTP 1 mM, dithiothreitol 5 mM) and 100 mCi of [ 32 P]UTP were added to 1610 7 nuclei and incubated at 258C for 25 min. RNA was extracted by mixing the nuclear suspension with 400 ml of RNAzol and equal counts per minute were hybridized with appropriate cDNA on nitrocellulose at 658C for 36 h before autoradiography.
Quanti®cation of DNA fragmentation DNA fragmentation was measured using a previously reported ®lter elution assay (Solary et al., 1993) . Exponentially growing cells were pre-labelled by adding 0.02 mCi/ml of [2-
14 C]thymidine in the culture medium for 2 days. Then, cells were chased in isotope-free medium overnight. Approximately 1.0610 6 14 C-labelled cells or 14 C-labelled nuclei were loaded onto a protein absorbing ®lter (Polyvinylidene¯uorure ®lters, 0.65 mm pore size, 25 mm diameter; Durapore membrane, Millipore, St Quentin, France). Cells or nuclei were then washed once with 5 ml of ice-cold PBS. Lysis was subsequently performed with 5 ml of LS10 buer (0.2% sodium sarkosyl, 2 M NaCl, 0.04 M EDTA, pH 10.0). Filters were washed with 7 ml of 0.02 M EDTA, pH 10. DNA was depurinated by adding 0.4 ml of 1N HCl at 658C for 45 min, then released from the ®lters by adding 2.5 ml of 0.4 N NaOH for 45 min at room temperature. Radioactivity was counted by liquid scintillation spectrometry in each fraction (wash, lysis, EDTA wash and ®lter). DNA fragmentation was measured as the fraction of d.p.m. in the lysis fraction plus EDTA wash relative to the total intracellular d.p.m.
Analysis of DNA fragmentation by agarose gel electrophoresis
Cellular DNA from whole cells or isolated nuclei was extracted by a salting-out procedure as described previously (Miller et al., 1988) . Electrophoresis was performed in a 1.8% agarose gel in Tris-borate-EDTA buer (pH 8) at 20 Volts for 15 h. After electrophoresis, DNA was visualised by ethidium bromide staining.
Western blot analysis
After treatment, cells were washed twice in PBS, lysed in lysis buer (150 mM NaCl, 1 mM KH 2 PO 4 , 1 mM EGTA, 1 mM Na 3 VO 4 , 5 mM MgCl 2 and 10% glycerol containing PmsF 0.1 mM, Aprotinin 0.15 U/ml, Pepstatin 1 mg/ml) and centrifugated for 15 min at 15 000 g. Fifty mg proteins of supernatants (Smith et al., 1985) were separated by SDS ± PAGE using a 12% polyacrylamide gel and electroblotted to PVDF membrane (BioRad, Ivry-sur-Seine, France). After blocking non-speci®c binding sites overnight by 5% nonfat milk in TPBS (PBS, Tween 20 0.1%), the membrane was incubated for 2 h at room temperature with anti-human procaspase-2 monoclonal antibody that recognizes both the long and the short isoforms of the protein (Transduction laboratories, Lexington, KY), washed twice with TPBS, further incubated with horseradish peroxidase-conjugated goat anti-mouse antibody (Jackson ImmunResearch Laboratories, West Grove, PE) for 30 min at room temperature and washed twice with TBPS. Immunoblot was revealed using enhanced chemioluminescence detection kit (Amersham, Les Ulis, France) by autoradiography. For PARP and procaspase-3 cleavage analyses, cells were lysed in SDS ± PAGE sample buer (125 mM Tris-HCl, pH 6.8, 10% b-mercaptoethanol, 4.6% SDS, 20% glycerol and 0.003% bromophenol blue) and cell lysates were subjected to SDS ± PAGE on a 8% polyacrylamide gel. The 116 kDa native PARP protein and its 85 kDa cleavage product were detected by immunoblotting with anti-human PARP polyclonal antibody (Vic. 5, kindly given by Dr G De Murcia) and horseradish-peroxidase conjugated anti-rabbit antibody (Amersham, Les Ulis, France) as described above. A rabbit polyclonal anticaspase-3-p17 antibody (kindly provided by Dr D Nicholson) that recognizes both procaspase-3 and its p19 and p17 subunits (Schlegel et al., 1996) was used to detect procaspase-3 activation in apoptotic U937 cells.
